Both erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) are common in the aging male. Numerous clinical trials have demonstrated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5-Is) for treating LUTS/BPH with/without ED. However, the influence of BPH on prostatic PDE5 expression has never been studied. A testosterone-induced rat model of BPH was developed and human hyperplastic prostate specimens were harvested during cystoprostatectomy. PDE5, nNOS, eNOS and α 1 -adrenoreceptor subtypes (α 1a ARs, α 1b ARs and α 1d ARs) were determined with real-time RT-PCR for rat tissues whilst PDE5 and α 1 -adrenoreceptor subtypes were determined in human samples. PDE5 was further analyzed with Western-blot and histological examination. Serum testosterone was measured with ELISA. The rat BPH model was validated as having a significantly enlarged prostate. PDE5 localized mainly in fibromuscular stroma in prostate. Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH, along with increased expression of nNOS and α 1d ARs for rat tissues and α 1a ARs for human BPH. The upregulation of PDE5 in the hyperplastic prostate could explain the mechanism and contribute to the high effectiveness of PDE5-Is for treating LUTS/BPH. Fibromuscular stroma could be the main target for PDE5-Is within prostate.
. This disorder is typically characterized by enlargement of the prostate gland, constriction of the urethra, and the emergence of LUTS. Besides prostatectomy, present pharmaceutical treatments for LUTS/BPH are aimed at relieving symptoms and slowing the progression of the disease. Current oral medical treatment options are 1) α -adrenoceptor antagonists (α -blockers, ABs) which reduce urethral resistance by attenuating the tension of smooth muscle (SM) fibers located in the prostate 2) 5α -reductase inhibitors (5ARIs) which are involved in the hormonal control of prostate growth 3) muscarinic receptor antagonists (MRAs) and 4) a "new emerging treatment" phosphodiesterase type 5 inhibitors (PDE5-Is) 3, 4 . Several clinical studies have demonstrated the efficacy and safety of PDE5-Is in treating LUTS/BPH. We recently performed a systematic review and network meta-analysis including 64 RCTs with 28196 participants comparing the effectiveness of different oral drug therapies for LUTS/BPH 5 . This data showed that among all the drug treatments, PDE5-Is combined with ABs ranked highest in efficacy for decreasing the international prostate symptom score (IPSS) including total score, storage subscore and voiding subscore. PDE5-Is used alone also showed promising efficacy, with the exception of not improving maximum flow rate (Q max ). However, the mechanisms by which PDE5-Is alleviates LUTS/BPH remains unclear despite the performance of several basic science studies. Recent experimental studies reported a functional role of PDE5 in lower urinary tracts and suggested a potential significance of the PDE5-nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway in the control of urogenital SM Histological examination. Differential histopathology was observed between human and rat BPH by H-E and Masson's trichrome staining. Specifically, in the rat BPH model, the hyperplasia of the prostate occurred mainly in the epithelium, whereas the stromal component decreased (mainly through the loss of collagen fibers, not SM) (Figs 2a,b and 3a). In contrast, in the human BPH sample, both stroma (mainly through increased SM) and epithelia increased significantly (even though there was a loss of collagen fibers) (Figs 2c,d and 3b).
Immunostaining. As shown in Fig. 4 , immunohistology demonstrated PDE5 was present in the rat prostate, predominantly in fibromuscular stroma cells and endothelial and SM cells of blood vessels. The human prostate also demonstrated stromal immunolocalization of PDE5. Negative controls omitting the primary antibody failed to stain and positive control using rat and human lung tissue showed a strong immune positivity. Furthermore, the localization of nNOS in human prostate was also investigated, nNOS was partly colocalized with PDE5 in stromal matrix (Fig. 4) .
The mRNA expression of PDE5 and related molecules. Expression of PDE5, nNOS, eNOS, α 1a ARs, α 1b ARs, α 1d ARs mRNA were determined using quantitative real time RT-PCR in the rat model (Fig. 5) . BPH upregulated PDE5 expression by approximately 2-fold at the gene level (P = 0.001). Real time RT-PCR also showed that nNOS (P = 0.003) and α 1d ARs (P < 0.001) were augmented significantly in BPH group but with no change in the level of eNOS, α 1a ARs and α 1b ARs. The expression of PDE5, α 1a ARs α 1b ARs and α 1d ARs mRNA were also determined in human prostate (Fig. 6 ). BPH equally upregulated PDE5 and α 1a ARs expression by 2.5-fold (P = 0.006, P = 0.02, respectively) with no change of α 1b ARs and α 1d ARs expression.
The translational expression of PDE5. Expression of PDE5 protein was quantified by Western blot analysis (Fig. 7) . Two major protein bands were detected at a molecular weight of 85 and 95 kDa, as reported in our previous study 10 . A significant 1.8-fold and over 3-fold increase of PDE5 at translational level was found for BPH rat (P = 0.013) and human (P < 0.001), respectively.
Discussion
Our T induced BPH rat model was validated through hyperplasia of the prostate and seminal vesicle (androgen-sensitive organs) with both organ weights significantly increasing. We observed body weight loss with T supplementation, which may be due to increased daily activity and an increased ratio of lean body mass/fat body mass. In parallel with previous observations 11, 12 , T injection mainly led to a notable involution of acinar epithelium hyperplasia, such as increased acinus amount, papillary fronds protruding into the glandular cavities and thickening of the epithelial layer while the stromal compartment was relatively decreased. Masson's trichrome staining further quantified that the BPH epithelia was significantly increased compared with control even though the SM content remained unchanged. In contrast, in the human condition, a predominant stromal hyperplasia was observed with an increase in SM of 2.2-fold.
In both rat and human prostate tissue, PDE5 gene and protein are highly expressed and was immunodistributed exclusively in the stroma. Our finding is in agreement with Fibbi et al. 6 that PDE5 was immunolocalized only in the fibromuscular stroma and vascular (endothelial and SM cells) in the rat and human prostate with no immunoreactivity in the glandular area. However, it contrasts with the findings by Ückert et al. 8 that the glandular and subglandular areas of human prostate also expressed PDE5. This disparity in immunolocalization of PDE5 could be attributed to the different primary antibodies employed as well as the different sources of tissue. In the study of Fibbi et al., prostate tissue was obtained from BPH patients while Ückert et al. study obtained tissue from prostate cancer patients. However, Wang et al. recently found PDE5 was expressed in both acinar epithelium as well as periacinar SM and lobe-specific PDE5 expression patterns were observed in this study 13 . They speculated that such expression might be associated with glandular secretory function. The stroma-predominant distribution of PDE5 would explain the functional role of PDE5-Is in the control of prostatic SM. In organ bath studies, we and others showed that the exposure of isolated rat or human prostate tissues to PDE5-Is could produce a relaxation of precontracted prostatic strips 10, 14 . Furthermore, our result of double-immunofluorescent labeling of PDE5 and nNOS from present study showed that these two proteins partly colocalize to prostatic fibromuscular stroma, providing further support for a functional role of PDE5-Is in the NO/cGMP mediated relaxation of prostatic SM.
Importantly, our data for the first time demonstrates an increased expression of PDE5 gene and protein in both the rat and human hyperplastic prostate, with a more significant increase observed in human BPH than in that of rat. We did not perform image quantification for PDE5 immunohistology since the results of quantitative RT-PCR and Western blot are more convincing for quantification. Increased PDE5 expression may be associated with elevated T level. Our findings in the prostate are broadly consistent with other lower urinary tract tissues (corpus cavernosum, bladder and vas deferens) that the expression of PDE5 is T regulated [15] [16] [17] [18] . In our rat model, after 28 days T supplementation, a significant increase in serum T level was detected by ELISA. For human BPH, it is well known that its development is closely associated with androgens and anti-androgen therapy with 5ARIs are effective for larger prostate over 40 ml, although increased estrogen/T ratio seems more important for BPH development 19 . In particular, dihydrotestosterone (DHT) was assumed to play a causative role in the etiology of BPH although this theory still remains speculative and controversial. Previous studies [20] [21] [22] reported levels of intraprostatic DHT increased but these findings were not confirmed by later study 23 , probably due to different methods of tissue retrieval, methods of tissue processing and assays of androgen determination used 24 . In addition, the elevated PDE5 expression may be ascribed to the stromal hyperplasia and increased SM content. Lin et al. reported that PDE5 gene is not directly regulated by T and the decreased expression of PDE5 in castrated animals is due to reduced SM content 25, 26 . Indeed, the stroma-predominant human BPH could contribute to greater PDE5 expression than that of epithelium-predominant rat BPH, as observed in our study. However, in our rat model, histological quantification showed that connective tissue decreased while SM content remained unchanged. Furthermore, in our previous studies on a castrated rat model 10 , the expression of PDE5 was decreased significantly despite a clear relative increase of the stromal layer observed. Therefore, the increased expression of PDE5 observed in our study is more likely to relate to increased gene and protein expression rather than to a change in morphology.
The upregulation of PDE5 in hyperplastic prostate could provide a rationale for the high efficacy of PDE5-Is for treating patients with LUTS/BPH with/without ED. It is well known that prostate enlargement is aging related 2 . In our study, the normal prostate was collected from young brain-dead men with the average age of 29 years old, while BPH specimens were harvested from the elderly with the mean age of 67 years old. Samples included in our study could represent clinical scenarios. We didn't care the location of tumor in bladder. Since the first clinical trial conducted by Sairam et al. 27 and safety of PDE5-Is for treating LUTS/BPH. Our recent systematic review and network meta-analysis 5 showed that among all the drug treatments, PDE5-Is combined with ABs ranked highest in efficacy for relieving IPSS total score, storage subscore and voiding subscore. PDE5-Is alone also showed promising effect except on Q max . Although a number of basic investigations have been done, the mechanisms involved in this treatment are still unclear. To date, a consensus has been reached that the potential mechanisms of PDE5-Is in treating LUTS/BPH are multifactorial 28 : (1) Slight-to-moderate relaxation of muscle tone in prostate and bladder; (2) Significant dilation of local blood vessels which provide adequate Figure 6 . mRNA expression of PDE5 and α 1 -adrenoreceptor subtypes (α 1a ARs, α 1b ARs and α 1d ARs) in human prostate (n = 9, 3 replicates per experiment). Boxes, mean; bars, ± S.E.M; **P < 0.01 vs. control; *P < 0.05 vs. control. Additionally, expression of other molecular components involved pathways associated with prostatic SM contraction and relaxation were determined in the rat prostate. It was found that several of these genes were differentially modulated by BPH. In rat model, nNOS and α 1d ARs mRNA were significantly increased with no change for eNOS, α 1a ARs and α 1b ARs. Our investigation of α 1 AR subtypes was consistent with Kojima et al. study, although a different BPH rat model was used 29 . Also, Hampel et al. found that in the lower urinary tract, upregulation of α 1d ARs correlated with severe bladder hypertrophy and bladder outlet obstruction (BOO) 30 . These results suggested that α 1d ARs may play a crucial role in rat BPH and BOO. In human, α 1 ARs is richly expressed in the prostate and excessive activity of α 1 -adrenergic SM contraction appears to be a common feature of symptomatic BPH 31 . Moreover, previous quantification of α 1 ARs mRNA expression within human prostate has revealed that α 1a ARs predominates, followed by α 1d ARs and α 1b ARs 32 . This predominance of α 1a ARs is reportedly more marked in the hyperplastic prostate. Immunohistochemisty showed that the immunoreactivity for α 1a ARs was exclusively located in the stroma and we consistently found a 2.5-fold increase of α 1a ARs expression 33, 34 . The expression of α 1b ARs and α 1d ARs were also examined in human prostate and no significant difference was observed. This discrepancy of α 1 -adrenoreceptor subtypes mRNA expression between human and rats BPH could be explained by differences in tissue morphometry. The differential expression and role of different NOS isoforms in the prostate and BPH is interesting and would need to be defined through further experimentation.
In current study, inflammation almost always accompanied BPH. It would be also interesting to further examine the inflammatory factors in prostate and explore whether prostatitis could affect the expression of PDE5 and the efficiency of its inhibitors in BPH/prostatitis patients. In conclusion, our data is the first report demonstrating an increase of PDE5 gene and protein expression both in rat and human hyperplastic prostate. Furthermore, the upregulation of PDE5 in BPH would enhance the efficacy of PDE5-Is within prostate and could therefore explain the possible mechanism and provide rationale for the use of PDE5-Is in treating patients with LUTS/BPH. In addition, fibromuscular stroma cells as well as endothelial and SM cells of blood vessels could be the main target tissue of PDE5-Is in the prostate.
Materials and Methods
Animal protocol. A total of 30 specific-pathogen-free (SPF) grade male Wistar rats (12 weeks), weighing 250-300 g, were used. Rats were randomly divided into two groups and fed water and rat chow ad libitum. One group (n = 15) were treated with 0.1 ml sesame oil as controls and the other (n = 15) were subcutaneously injected with 2 mg/d testosterone propionate (Shanghai Tongyong Medical Co., Ltd, Shanghai, China) for 28 days. Rats were weighed and sacrificed under anesthesia using a euthanasia solution containing 10% [w/v] chloral hydrate on day 29. The blood was collected from the abdominal aorta. The whole ventral prostatic lobes, seminal vesicles and bladder were harvested and weighed. Prostatic strips of 1 × 1 × 0.5 cm were put into 10% [v/v] neutral buffered formalin for histological examination and another portion of strips were put into RNA Sample Protector (Takara Bio. Inc.,Otsu, Shiga, Japan) for PCR analysis with the rest of the tissue frozen in liquid nitrogen and saved at − 80 °C. All animal experimental procedures were performed strictly in accordance with the care and use of laboratory animals (National Research Council, Washington, DC) and the related ethical regulations of our university.
Human specimens. Nine human normal prostate samples are obtained from young brain-dead men (mean age, 29.1 ± 1.7 years) undergoing organ donation surgery. Nine human BPH samples are obtained from patients (mean age, 67.7 ± 2.1 years) undergoing cystoprostatectomy for infiltrating bladder cancer without prostate infiltration and LUTS/BPH. Immediately after removal, tissue specimens were shock frozen in liquid nitrogen and stored at − 80 °C for subsequent analysis. All tissue samples were obtained after the approval of the Hospital Committee for Investigation in Humans and after receiving written informed consent from all patients or their relatives involved. Human study was conducted in accordance with the principles of the Declaration of Helsinki.
Serum testosterone level.
After blood was collected, serum was then isolated as the supernatant fraction following centrifugation at 3000 g for 10 min. The measurement of T concentrations was via enzyme-linked immunosorbent assay (ELISA) according to the BlueGene Biotech (Shanghai, China) protocol.
Total RNA extraction and real-time RT-PCR. Total RNA was isolated from the frozen tissues using TaKaRa MiniBEST Universal RNA Extraction Kit (Takara Bio. Inc., Otsu, Shiga, Japan) according to the manufacturer's protocol. 100 ng of RNA was added in the one-step real-time RT-PCR reaction system (Takara Bio. Inc.,Otsu, Shiga, Japan). The whole system was amplified in a 96-well plate in a 25 μ l reaction volume with all samples run in triplicate, using a CFX96 Touch Real-Time PCR Detection System (BioRad, USA). The experimental protocol utilized was first reverse transcription (42 °C 5 min, 95 °C 10 s), followed by an amplification program repeated for 40 cycles (95 °C for 5 s, then 60 °C for 30 s), using SYBR Green measurement. For rat prostate tissue, the following targets were amplified: PDE5, neuronal NOS (nNOS), endothelial NOS (eNOS), and α 1 -adrenoreceptor subtypes (α 1a ARs, α 1b ARs and α 1d ARs), and for human tissue, PDE5, α 1a ARs, α 1b ARs and α 1d ARs were investigated. Primer sequences are shown in Table 2 . For relative quantification, gene expression was normalized to expression of β -actin housekeeping gene and compared by 2 −ΔΔCT method. dropwise for 10 min. The sections were subsequently washed with distilled water, differentiated in phosphomolybdic-phosphotungstic acid solution for 10 min, and incubated with blue staining solution for 5-10 min. Rinsed briefly in distilled water and differentiated in 1% acetic acid solution for 2 minutes. After dehydrated quickly through 95% alcohol, absolute alcohol, the sections were cemented using neutral gum for observation. Using this procedure, prostatic stroma SM cells were stained red, collagen fibers were stained blue and epithelial cells were stained orange. In each sample, we analyzed three areas under magnification (×100). The area percentage of SM, collagen fibers and glandular epithelium were quantitated with Image pro plus 5.0, respectively.
SDS-PAGE and
Immunohistochemistry. Sections for immunohistochemistry were deparaffinized in xylene followed by graded alcohols. Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) and heated to 96 °C for 3 min. Endogenous peroxidase activity was blocked by using 3% [v/v] H 2 O 2 solution in methanol at room temperature for 10 min. Sections were incubated with 15% [v/v] normal goat serum for 1 h at 37 °C to block nonspecific binding. 100 μ l appropriately diluted PDE5A primary antibody (1:100) was applied to the sections on the slides and incubated in a humidified chamber at 4 °C overnight. Then the sections were stained by routine immunohistochemistry methods. Negative controls were performed for all samples by omitting the primary antibodies. Rat lung tissue was used as a positive control for PDE5A staining. All the stained sections were imaged using Olympus-DP72 light microscope (Olympus, Japan).
Immunofluroscence. Human prostate were embedded in Tissue-Tec OCT compound (SakuraFinetek Japan, Tokyo, Japan) and snap frozen. Then tissue was sectioned in 10 μ M thick slices and thaw, mounted onto glass slides using a cryostat (Leica CM 1850, Wetzlar, Germany), air-dried, and fixed for 10 min in ice-cold acetone. Slides were washed in PBS and then incubated for 2 h in a mixture of PBS supplemented with 0.2% [v/v] Triton X-100 and 0.1% [w/v] bovine serum albumin, followed by incubation overnight with the primary antibody (rabbit polyclonal to PDE5A, 1:100) and antibody mixture of the PDE5A antibody (1:100) and goat polyclonal to nNOS (1:50, Abcam, ab1376 Cambridge, UK). The secondary antibodies employed to visualize the localization of the two primary antibodies (Jackson ImmunoResearch Inc. West Grove, PA, USA) were Cy3-conjugated goat anti-rabbit IgG (1:1000) and Cy2-conjugated donkey anti-goat IgG (1:400). DAPI was used for staining the nucleus. Negative controls were performed for all samples by omitting the primary antibodies. Human lung tissue was used as a positive control for PDE5A staining. Visualization was done with a laser microscope (Olympus, Tokyo, Japan). Colocalization analysis was performed using NIS-Elements Viewer 3.20 (Nikon, Japan). All experimental protocol were approved by the research committee of Wuhan University.
Statistical analysis.
Results are expressed as the mean ± SD in table and mean ± SEM in bar graph.
Student's t test was used to analyze the differences between two groups. Statistical analyses were performed using GraphPad Prism v5.0 (La Jolla, CA). A P < 0.05 was considered statistically significant.
Ethical standards. All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee of Wuhan University and the principles of the Declaration of Helsinki. All participants gave written informed consent before taking part in the study. All procedures performed in studies involving animals were in accordance with the care and use of laboratory animals (National Research Council, Washington, DC) and the ethical standards of Wuhan University.
All experimental protocol were approved by the research committee of Wuhan University.
